HOSPITAL UNIVERSITARIO RUBER
Departamento
University of Montreal
Montreal, CanadáPublicaciones en colaboración con investigadores/as de University of Montreal (5)
2021
-
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
npj Breast Cancer, Vol. 7, Núm. 1
2016
-
Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer
Breast Cancer: Basic and Clinical Research, Vol. 10, pp. 77-84
2015
-
"New" metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy
Breast Cancer Research, Vol. 17, Núm. 1
-
Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial
Breast Cancer Research and Treatment, Vol. 154, Núm. 3, pp. 509-520
-
Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane
Journal of Clinical Oncology, Vol. 33, Núm. 6, pp. 594-601